Ignite Creation Date:
2025-12-24 @ 11:48 PM
Ignite Modification Date:
2026-02-25 @ 12:56 AM
Study NCT ID:
NCT02787551
Status:
COMPLETED
Last Update Posted:
2022-03-25
First Post:
2016-05-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Sponsor:
Sanofi
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-07-06
Start Date Type:
ACTUAL
Primary Completion Date:
2018-05-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-11-17
Completion Date Type:
ACTUAL
First Submit Date:
2016-05-26
First Submit QC Date:
None
Study First Post Date:
2016-06-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-05-23
Results First Submit QC Date:
None
Results First Post Date:
2019-06-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-03-15
Last Update Post Date:
2022-03-25
Last Update Post Date Type:
ACTUAL